PRNB - Principia Biopharma Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
23.945
-0.145 (-0.60%)
As of 3:01PM EST. Market open.
Stock chart is not supported by your current browser
Previous Close24.090
Open24.160
Bid23.680 x 3000
Ask23.960 x 900
Day's Range23.536 - 24.235
52 Week Range22.000 - 36.000
Volume20,248
Avg. Volume176,390
Market Cap571.661M
Beta (3Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-15.866
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est40.50
Trade prices are not sourced from all markets
  • GlobeNewswire6 days ago

    Principia Biopharma to Present at 27th Annual Credit Suisse Healthcare Conference

    Principia Biopharma Inc. (PRNB), a clinical-stage biopharmaceutical company dedicated to bringing transformative oral therapies to patients with significant unmet medical needs in immunology and oncology, today announced that management will present at the 27th Annual Credit Suisse Healthcare Conference on Thursday, November 15, 2018, at 8:35 a.m. MT (10:35 a.m. ET) at the Phoenician in Scottsdale, Arizona. The presentation will be available via live webcast from the “Events and Presentations” page of the “Investors” section of the Company’s website. Principia Biopharma is a clinical-stage biopharmaceutical company dedicated to bringing transformative oral therapies to patients with significant unmet medical needs in immunology and oncology.

  • GlobeNewswire8 days ago

    Principia Biopharma Reports Third Quarter Financial Results

    SOUTH SAN FRANCISCO, Calif., Nov. 06, 2018 -- Principia Biopharma Inc. (Nasdaq: PRNB), a clinical-stage biopharmaceutical company dedicated to bringing transformative oral.

  • GlobeNewswire21 days ago

    Principia Biopharma Appoints Dolca Thomas, M.D. as Chief Medical Officer

    - Succession designed to lead Principia through next phase of growth as a clinical-stage company - SOUTH SAN FRANCISCO, Calif., Oct. 24, 2018 -- Principia Biopharma Inc..

  • Health Care Digest: Winning the war for biotech talent, dialysis companies spend big on Prop. 8, and more
    American City Business Journals23 days ago

    Health Care Digest: Winning the war for biotech talent, dialysis companies spend big on Prop. 8, and more

    Biotech companies must do more to train, mentor and guide millennials, including pairing them with older colleagues, according to members of a recent panel.

  • GlobeNewswire26 days ago

    Principia Biopharma Announces PRN1008 Receives Orphan-Drug Designation from FDA for Treatment of Immune Thrombocytopenic Purpura

    Principia Biopharma Inc. (PRNB), a clinical-stage biopharmaceutical company dedicated to bringing transformative oral therapies to patients with significant unmet medical needs in immunology and oncology, today announced that PRN1008, an oral, reversible covalent Bruton’s Tyrosine Kinase (BTK) inhibitor, has been granted orphan-drug designation by the U.S. Food and Drug Administration (FDA) for the treatment of patients with immune thrombocytopenic purpura (ITP). Principia is currently conducting a Phase 2 clinical trial to evaluate the safety and efficacy of PRN1008 in patients with ITP.

  • GlobeNewswire29 days ago

    Principia Achieves $10 Million in Additional Milestones Related to Development of PRN2246/SAR442168

    Principia Biopharma Inc. (PRNB), a clinical-stage biopharmaceutical company dedicated to bringing transformative oral therapies to patients with significant unmet medical needs in immunology and oncology, today announced the achievement of $10 million in additional milestones related to successful development activities conducted by Principia as part of the clinical development of PRN2246. PRN2246, also known as SAR442168, is a Bruton’s tyrosine kinase (BTK) inhibitor that crosses the human blood-brain barrier and modulates immune cell function in the brain for the potential treatment of central nervous system (CNS) diseases. PRN2246 is being developed under a collaboration agreement with Sanofi, a company committed to discovering and developing new treatment options for people living with multiple sclerosis (MS).

  • GlobeNewswire2 months ago

    Principia Biopharma to Present at 2018 Leerink Partners Roundtable Series: Rare Disease & Immuno-Oncology

    SOUTH SAN FRANCISCO, Calif., Sept. 26, 2018-- Principia Biopharma Inc., a clinical-stage biopharmaceutical company dedicated to bringing transformative oral therapies to patients with significant unmet ...

  • GlobeNewswire2 months ago

    Principia Biopharma Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares

    SOUTH SAN FRANCISCO, Calif., Sept. 18, 2018-- Principia Biopharma Inc., a clinical-stage biopharmaceutical company dedicated to bringing transformative oral therapies to patients with significant unmet ...

  • ACCESSWIRE2 months ago

    Today’s Research Reports on Stocks to Watch: Unity Biotechnology and Principia Biopharma

    NEW YORK, NY / ACCESSWIRE / September 17, 2018 / Biotech stocks Unity Biotechnology and Principia Biopharma had exciting trading days on Friday. Shares of Unity saw more gains on Friday after exploding last Thursday when its CEO spoke on CNBC’s “Power Lunch” about the company’s plans. Amazon CEO Jeff Bezos is an investor in the company.

  • The Wall Street Journal2 months ago

    [$$] Principia Biopharma Prices IPO at High End of Range

    Principia Biopharma Inc. said its initial public offering raised about $106 million to fund development of oral therapeutics focused on immunology and oncology.

  • GlobeNewswire2 months ago

    Principia Biopharma Announces Pricing of Initial Public Offering

    Principia Biopharma Inc. (Principia or the Company, Nasdaq: PRNB), a clinical-stage biopharmaceutical company dedicated to bringing transformative oral therapies to patients with significant unmet medical needs in immunology and oncology, today announced the pricing of its initial public offering of 6,250,000 shares of common stock at a public offering price of $17.00 per share. The gross proceeds to Principia, before deducting underwriting discounts and commissions and offering expenses, are expected to be approximately $106.25 million. All of the common stock is being offered by Principia.  The shares of the Company’s common stock are expected to begin trading on the Nasdaq Global Select Market on September 14, 2018 under the trading symbol "PRNB." The offering is expected to close on September 18, 2018, subject to customary closing conditions.